<DOC>
	<DOCNO>NCT02089412</DOCNO>
	<brief_summary>This open-label , single-dose , randomize crossover study single oral 10-mg tablet dos administer either overnight fast combination standard high-fat meal healthy subject .</brief_summary>
	<brief_title>A Study Determine Effect High-Fat Meal Rate Extent E2006 Absorption Healthy Subjects</brief_title>
	<detailed_description>The study 2 phase : Prerandomization Randomization . The Prerandomization Phase consist 2 period : Screening Baseline ( Baseline Period 1 ) , subjectï¿½s study eligibility determine baseline assessment conduct . During phase , eligible subject randomize 1 2 treatment sequence receive single oral dos E2006 10 mg fast fed condition . The Randomization Phase consist 3 period : administration first randomize dose ( Treatment Period 1 ) , baseline second randomize dose ( Baseline Period 2 ) , administration second randomize dose ( Treatment Period 2 ) .</detailed_description>
	<criteria>Inclusion Criteria 1 . Healthy male female , age 18 55 year 2 . Body mass index great 18 less equal 32 kg/m2 Screening 3 . All female must nonchildbearing potential , define postmenopausal woman ( define least 12 month consecutive amenorrhea , appropriate age group without know suspected cause ) subject sterilize surgically otherwise prove sterile ( eg , bilateral tubal ligation surgery least 6 month prior dose , hysterectomy , bilateral oophorectomy surgery least 2 month prior dose ) . In addition , female must negative serum Bhuman chorionic gonadotropin test result Screening . 4 . Males abstinent undergone successful vasectomy , partner woman childbearing potential must use , partner must use highly effective method contraception ( eg , condom plus spermicide , condom plus diaphragm spermicide , intrauterine device start least 1 menstrual cycle prior start study drug throughout entire study period 30 day [ longer appropriate ] last dose study drug ) 5 . Are willing able comply aspect protocol 6 . Provide write informed consent Exclusion Criteria 1 . Any subject know history malaria travel country know malarial risk ( ie , designate `` high '' `` moderate '' risk country accord list available http : //www.cdc.gov/malaria ) within last year 2 . Subjects history bowel resection , malabsorptive disorder , severe gastroparesis , gastrointestinal procedure purpose weight loss ( include Lapband ( TM ) ) , would slow gastric empty potentially affect PK profile E2006 3 . Subjects know history clinically significant drug food allergy know allergy hypersensitivity capsule tablet ingredient 4 . Subjects experience weight loss gain great 10 % Screening prior dose 5 . Subjects clinically significant illness require medical treatment within 8 week clinically significant infection within 4 week dose 6 . Subjects clinically abnormal symptom organ impairment find medical history , symptom sign , vital sign measurement , electrocardiogram ( ECG ) finding , laboratory test result require medical treatment find medical history screen baseline 7 . Subjects know positive human immunodeficiency virus , subject positive hepatitis B hepatitis C screen test result 8 . Subjects history drug alcohol dependency abuse ( define The Diagnostic Statistical Manual Mental Disorders V criterion ) within approximately 2 year prior Screening , positive urine drug test result Screening Baseline 9 . Subjects receive blood product within 4 week , donate blood within 8 week , donate plasma within 1 week dose 10 . Subjects use hormonal replacement therapy within 3 month prior dose 11 . Subjects use drug , overthecounter medication , nutritional supplement ( eg , product contain St. John 's wort ) , excessive dos vitamin ( opinion principal investigator ) , herbal preparation , food beverage know modulate cytochrome P450 ( [ CYP ] eg , CYP3A4 ) transporter within 4 week prior dose , unwilling abstain use study 12 . Subjects engage intense physical activity within 1 week prior Baseline ( eg , weight training ) 13 . Subjects smoke used tobacco nicotinecontaining product within 3 month prior dose 14 . Subjects habitually consume 400mg caffeine per day 15 . Subjects participate ( receive investigational product ) another clinical trial le 1 month ( 5 elimination halflives investigational product ) prior dose currently enrol another clinical trial 16 . Subjects disease may influence outcome study , psychiatric disorder disorder gastrointestinal tract , liver , kidney , respiratory system , endocrine system , hematological system , neurological system , cardiovascular system , subject congenital abnormality metabolism , subject condition would make , opinion investigator , unsuitable study , opinion investigator , likely complete study reason</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>Healthy Subjects</keyword>
	<keyword>Absorption</keyword>
	<keyword>High-Fat Meal</keyword>
</DOC>